Welcome to our dedicated page for Cytodyn news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn stock.
CytoDyn Inc. (CYDY) is a clinical-stage biotechnology and oncology company whose news flow centers on the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Company announcements frequently highlight progress in solid tumor oncology, particularly metastatic triple-negative breast cancer (mTNBC) and metastatic colorectal cancer (mCRC), as well as broader CCR5-related research.
Investors following CYDY news can expect updates on clinical trial milestones, including Phase 2 studies in mCRC and planned Phase 2 proof-of-concept and combination trials in mTNBC. Press releases and shareholder letters describe retrospective survival analyses, PD-L1 upregulation findings, and the company’s “prime and pair” strategy that combines leronlimab with immune checkpoint inhibitors. Conference-related news often covers poster and oral presentations at major oncology meetings such as the San Antonio Breast Cancer Symposium, European Society for Medical Oncology events, and AACR specialty conferences.
CytoDyn’s news stream also includes corporate and regulatory developments. Recent items have addressed the resolution of government investigations, an agreement in principle to settle a securities class action lawsuit, and stockholder approval of amendments to increase authorized common shares. Financing updates, such as the Standby Equity Purchase Agreement with Yorkville, provide insight into how the company plans to support its clinical programs.
In addition, CytoDyn issues periodic letters to shareholders that summarize operational rebuilding, regulatory interactions, and collaborations with academic centers in areas like glioblastoma, Alzheimer’s disease, and HIV cure research. For readers tracking CYDY, this news page offers a consolidated view of scientific data releases, trial progress, financing arrangements, and governance actions that shape the company’s development trajectory.
The Investor Group of CytoDyn Inc. (CYDY) expressed disappointment after the Delaware Court of Chancery denied their request to allow stockholders to vote on their five nominated director candidates. They criticized the company’s management for failing to secure FDA approval for Leronlimab and being under investigation by the SEC and DOJ, while also issuing a going concern disclosure. The Investor Group believes new leadership is essential for positive change.
CytoDyn Inc. (OTC-PINK: CYDY) announced that the Delaware Court of Chancery upheld its Board of Directors' rejection of a nomination notice from an activist group led by Paul Rosenbaum and Bruce Patterson. The court ruled that the notice did not comply with the company's by-laws, lacking essential information about supporters and possible conflicts. Consequently, any proxies or votes favoring the activist group's nominees will not be counted at the upcoming 2021 Annual Meeting on October 28, 2021, where shareholders as of September 1, 2021 can vote.
CytoDyn Inc. (OTCQB: CYDY) will provide a business update at the Emerging Growth Conference on October 13, 2021, from 1:00 PM ET to 3:00 PM ET, featuring key executives including Nader Pourhassan, Ph.D., and Scott Kelly, M.D. The presentation will consist of a 30-minute overview followed by a 90-minute Q&A session. CytoDyn is advancing leronlimab, a CCR5 antagonist, with FDA Fast Track designation for treating HIV and metastatic cancer. The livestream can be accessed here.
CytoDyn Inc. (OTCQB: CYDY) announced a new clinical study targeting triple-negative breast cancer (TNBC) utilizing leronlimab, a CCR5 antagonist. Led by Dr. Jangsoon Lee at MD Anderson Cancer Center, the study aims to assess the combination of leronlimab and immune checkpoint blockade (ICB) to enhance treatment efficacy. Leronlimab has received FDA Fast Track designation for HIV and metastatic TNBC. The company plans to explore leronlimab’s potential in various therapeutic areas, including SARS COVID-19 long-haulers and nonalcoholic steatohepatitis (NASH).
CytoDyn Inc. (OTCQB: CYDY) announced key management appointments, including Dr. Christopher Recknor as Senior Executive VP of Clinical Operations and Dr. Nitya Ray as Chief Operating Officer. This restructuring aims to streamline the BLA resubmission process and advance clinical development for leronlimab, a CCR5 antagonist with potential applications in HIV and cancer. The company is also preparing for upcoming trials, including for NASH and COVID-19 long-haulers. Dr. Ray's experience is expected to enhance regulatory submissions, while a strong inventory of leronlimab supports commercial readiness.
CytoDyn Inc. (OTCQB: CYDY) has filed a lawsuit against NSF International and Amarex Clinical Research for breach of contract, alleging failure to provide agreed services and significant delays in obtaining regulatory approval for its investigational drug, leronlimab. CytoDyn claims these failures have resulted in substantial damages and avoidable delays in clinical development. The company has simultaneously initiated arbitration to seek a resolution. Meanwhile, CytoDyn plans to resubmit its Biologics License Application (BLA) by early 2022, with upcoming trial submissions expected in November.
CytoDyn Inc. (OTC-PINK: CYDY) responds to an activist group's plan, asserting it lacks compelling strategic direction for cancer therapy approval. The company emphasizes its progress in developing leronlimab, a CCR5 antagonist, achieving faster advancements than prior ownership. Key points include support from top oncologists, a focus on Breakthrough Therapy designation, and a recent Phase 3 trial clearance in Brazil for IV treatment. CytoDyn warns shareholders against the activist group's misleading statements and conflicts of interest, advising no immediate action.
A group of long-time stockholders of CytoDyn Inc. (CYDY) has nominated five director candidates and released a white paper criticizing the company's borrowing practices. Since June 2018, CYDY has relied heavily on borrowing from Iliad Research and Trading, resulting in $142.5 million of convertible notes yielding only $125 million due to high costs. The group calls for accountability from current management, asserting the need for competent leadership to restore investor trust and maximize the company's potential.
CytoDyn Inc. (OTCQB: CYDY) announced a comprehensive business update to be presented by CEO Nader Pourhassan and CMO Scott Kelly at the Emerging Growth Conference on September 29, 2021. The presentation will last 20 minutes, followed by 40 minutes of Q&A.
CytoDyn is developing leronlimab, a CCR5 antagonist with potential uses in treating HIV, cancer, and post-COVID-19 symptoms. The FDA has granted Fast Track designation for two indications related to HIV and metastatic cancer. Phase 2 trials for NASH and long COVID are also underway.
A group of long-time stockholders of CytoDyn Inc. (OTC: CYDY) has announced a strategic plan to secure FDA approval for Leronlimab, a cancer therapy. They have nominated five experienced candidates for the Board, asserting that the current management's approach is ineffective. The plan aims to leverage precision medicine data, combine therapies, prioritize cancer targets, and partner with leading oncology companies. The Group believes this strategy could generate revenue and enhance shareholder value, urging stockholders to vote for their nominees on the WHITE proxy card.